ECSP992858A - ANTIBODIES AGAINST HUMAN CD40 - Google Patents

ANTIBODIES AGAINST HUMAN CD40

Info

Publication number
ECSP992858A
ECSP992858A ECSP992858A ECSP992858A EC SP992858 A ECSP992858 A EC SP992858A EC SP992858 A ECSP992858 A EC SP992858A EC SP992858 A ECSP992858 A EC SP992858A
Authority
EC
Ecuador
Prior art keywords
antibodies
antibodies against
against human
human
applicants
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Alejandro Aruffo
Diane Hollenbaugh
Anthony Siadak
Karen Berry
Linda Harris
Barbara Thorne
Jurgen Bajorath
William Huse
Herren Wu
Jeffry Watkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to ECSP992858 priority Critical patent/ECSP992858A/en
Publication of ECSP992858A publication Critical patent/ECSP992858A/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los solicitantes han descubierto nuevos anticuerpos CD40 anti-humanos quiméricos y humanizados que bloquean la interacción entre gp39 y CD40. Los anticuerpos CD40 de la presente invención son efectivos en la modulación de respuestas inmunes humorales contra antígenos que dependen de la célula T, artritis introducida por colágeno, y transplante de piel, y también son útiles por sus propiedades anti-inflamatorias.Applicants have discovered new chimeric and humanized anti-human CD40 antibodies that block the interaction between gp39 and CD40. The CD40 antibodies of the present invention are effective in modulating humoral immune responses against T-cell dependent antigens, collagen-introduced arthritis, and skin transplantation, and are also useful for their anti-inflammatory properties.

ECSP992858 1999-02-12 1999-02-12 ANTIBODIES AGAINST HUMAN CD40 ECSP992858A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ECSP992858 ECSP992858A (en) 1999-02-12 1999-02-12 ANTIBODIES AGAINST HUMAN CD40

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ECSP992858 ECSP992858A (en) 1999-02-12 1999-02-12 ANTIBODIES AGAINST HUMAN CD40

Publications (1)

Publication Number Publication Date
ECSP992858A true ECSP992858A (en) 2000-09-22

Family

ID=42043847

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP992858 ECSP992858A (en) 1999-02-12 1999-02-12 ANTIBODIES AGAINST HUMAN CD40

Country Status (1)

Country Link
EC (1) ECSP992858A (en)

Similar Documents

Publication Publication Date Title
BR9908045A (en) Antibodies against human cd40
IN2012DN00313A (en)
MX2009008918A (en) Activation of human antigen-presenting cells through clec-6.
UY28424A1 (en) RGI ANTIBODIES AND USES OF THE SAME.
CY1107802T1 (en) COMPOSITIONS AND METHODS FOR INDUCING SPECIFIC CELLULAR RESPONSES OF T-Lymphocytes
MY150237A (en) Cripto blocking antibodies and uses thereof
WO2005037190A3 (en) Multiplex vaccines
CR9562A (en) ANTI-CD40 HUMANIZED ANTIBODIES AND THEIR METHODS OF USE
PT699237E (en) ANTI-EGFR CHAIN FVS AND ANTI-EGFR ANTIBODIES
EP0671927A4 (en) HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST RESPIRATORY SYNCYTIAL VIRUS.
ECSP045470A (en) BIOLOGICAL PRODUCTS
HUP0400951A2 (en) An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
DE60141964D1 (en) LUMBAR
FR12C0004I1 (en)
YU28503A (en) Humanized anti-lt-betha-r antibodies
IL172854A0 (en) Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations
TR200102034T2 (en) Using antibodies for anti cancer vaccination
MX2022013393A (en) RECEPTORS OF CHIMERIC ANTIGENS DIRECTED AT CD19 AND USE THEREOF.
NO965395L (en) Human monoclonal antibodies specific for cell cycle-independent glioma surface antigen
TW200640947A (en) Novel polypeptide ligands for toll-like receptor 2 (TLR2)
WO2020172482A3 (en) Cd80 extracellular domain-fc fusion proteins for treating pd-l1 negative tumors
Lund et al. Signal sequence deletion and fusion to tetanus toxoid epitope augment antitumor immune responses to a human carcinoembryonic antigen (CEA) plasmid DNA vaccine in a murine test system
DK1000163T3 (en) Pseudomonas exotoxin A-like chimeric immunogens
UA94211C2 (en) Isolated fully human monoclonal anti-cd3 antibody
ECSP992858A (en) ANTIBODIES AGAINST HUMAN CD40